Estrogens, Conjugated

Winona launches national research initiative offering funding, mentorship, data support, and publication opportunities for emerging women's health researchers AUSTIN, Texas, June 1, 2026 /PRNewswire/ -- Menopause affects millions of women every year, yet research into menopause and women's health remains significantly underfunded. To help address that gap, Winona, a physician-led telehealth company focused on menopause and perimenopause care, today announced the launch of the Winona Research Initiative, a national program designed to make menopause and women's health research more accessible to early-career clinicians, medical students, residents, fellows, and early faculty. Continue Reading Two women smile as they look at a phone together. The initiative provides selected Winona Scholars with funding, mentorship, data support, publication opportunities, media visibility, and professional resources to conduct rapid-cycle research focused on menopause and women's health. Applications are now open on a rolling basis at . Winona created this program in response to a persistent funding gap in women's health research. A National Academies analysis found that only 8.8% of NIH grant spending from fiscal years 2013 to 2023 focused on women's health research, even as funding for women's health research declined as a share of total NIH grant spending over that period. The same report noted that women-specific life stages, including menopause, are not clearly prioritized within the current NIH structure. "Menopause affects millions of women, but the research infrastructure around it has not matched the scale of the need," said Dr. Michael Green, MD, Chief Medical Officer at Winona. "The Winona Research Initiative is about investing directly in the next generation of clinicians and researchers who can help improve how menopause is understood, studied, and treated." A National Program for Emerging Women's Health Researchers The Winona Research Initiative welcomes pre-med and medical students, OB-GYN residents, fellows, and early faculty with an interest in women's health research, particularly menopause. Applicants should be currently enrolled in, affiliated with, or recently graduated from a U.S. undergraduate, medical school, residency, fellowship, or early faculty program and have five to ten hours per week available for a six-to-eight-week rapid-cycle research project. Accepted Winona Scholars receive: A $3,000 scholarship stipend Additional financial support for conferences Mentorship and publication support Published research opportunities Media visibility and networking opportunities "Women deserve better health answers during perimenopause, menopause, and postmenopause," said Dr. Cathleen M. Brown, DO, Medical Director at Winona. "That starts with better research. By supporting early-career scholars, we can help build a stronger foundation for future care." Supporting Research to Shape the Future of Menopause Care The Winona Research Initiative is designed to help scholars pursue medical research that may otherwise be difficult to access early in their careers. Through mentorship, data support, and publication guidance, the program aims to help emerging researchers contribute to a stronger evidence base for menopause care. For Winona, the initiative reflects a broader commitment to improving how menopause is understood by patients, clinicians, researchers, and the public. "As a menopause care provider, Winona sees firsthand how much work remains to be done," said Dr. Michael Green, Chief Medical Officer at Winona. "The research gap is not abstract. It affects how women understand their symptoms, how clinicians guide treatment decisions, and how the healthcare system supports women through hormone changes over time." Applications Are Now Open Rolling applications are currently being accepted for the Winona Research Initiative. Applicants will be contacted with a decision within two to four weeks of application. Accepted scholars are expected to begin within four to six weeks of acceptance. Interested applicants can learn more and apply at . Universities, medical schools, and prospective partners can contact [email protected]. Press inquiries can be directed to [email protected]. Source National Academies of Sciences, Engineering, and Medicine, A New Vision for Women's Health Research About Winona Winona is a physician-led telehealth company focused on menopause and perimenopause care. Its board-certified physicians help women understand and find relief from symptoms such as hot flashes, night sweats, sleep disruption, mood changes, brain fog, vaginal dryness, intimacy issues, weight changes, hair thinning, and joint pain. When appropriate, Winona offers personalized treatment plans that may include hormone replacement therapy, bioidentical HRT, estrogen, progesterone, vaginal estrogen, and non-hormonal options. Winona also provides education and community support for women navigating hormone changes, perimenopause, menopause, and postmenopause. For more information, visit . SOURCE Winona 21% more press release views with Request a Demo

With ongoing shortages impacting estrogen therapy patches, Femring offers consistent access and a dual indication for women navigating multiple symptoms of menopause. EAST HANOVER, N.J., May 27, 2026 /PRNewswire/ -- Increasing demand for estrogen therapy coupled with a growing awareness and interest in the menopause market have led to supply disruptions with the estrogen patch. As women across the country continue to face frustration with hormone therapy patch shortages and inconsistent product availability, Femring is emerging as a readily available and accessible treatment option for those seeking a convenient transdermal alternative. Femring offers flexibility in treatment with two dosing strengths, as well as a 90-day dosing regimen, fitting into the busy active lifestyle of the modern menopausal woman. Femring, a prescription vaginal ring uniquely designed to deliver continuous systemic estrogen therapy through a convenient, long-acting vaginal ring replaced every 90 days. Femring is designed to support uninterrupted symptom relief without the variability patients may experience with other delivery methods. For women seeking an alternative to patches or daily therapies, Femring may offer a practical option that fits their lifestyle while helping maintain symptom control. "Women deserve confidence that their therapy will be available when they need it," said Dr. Rachel Rubin, MD. "As supply issues and treatment inconsistency continue to affect the market, Femring offers an established option physicians can prescribe, and patients can access. We also see this as an important opportunity to raise awareness about this dual-indication menopause treatment as Femring is the only FDA-approved product that treats both systemic issues like hot flashes as well as the genitourinary symptoms experienced in menopause." Healthcare providers are increasingly recognizing the importance of individualized treatment approaches in menopause care, particularly during periods of market disruption. Femring provides another evidence-based option to help support patient adherence and continuity of treatment. "Speaking with women who are navigating menopause today, they are sacrificing convenience in the middle of one of the busiest seasons of their lives," added AnneMarie Tipa, Millicent Pharma's Vice President of Sales and Marketing. "By increasing awareness of Femring, we hope to empower more women to have informed conversations with their healthcare providers about a 90-day treatment option that tackles multiple symptoms at once." Femring is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and moderate-to-severe vulvar and vaginal atrophy due to menopause. For more information about Femring, visit femring.com or speak with your healthcare provider. Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use . About Millicent Pharma Millicent Pharma is a leading specialty pharmaceutical company that offers multiple commercial products for women today, supporting its focus of advancing women's health through high quality and innovative solutions. More information can be found at About Femring Femring (estradiol acetate vaginal ring) is a prescription estrogen therapy designed to provide continuous systemic delivery of estradiol for up to 90 days. Femring is indicated for the treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. Patients should discuss the benefits and risks of hormone therapy with their healthcare provider. Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina. Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina. Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant. Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements. Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed. Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus ("fibroids"). Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching. Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue. For more information, talk with your healthcare provider. Media Contact: Andrea Tillman [email protected] SOURCE Millicent Pharma 21% more press release views with Request a Demo